Biosimilar structural comparability assessment by NMR: from small proteins to monoclonal antibodies
Оценка структурной сопоставимости биосимиляров методом ЯМР: от малых белков до моноклональных антител
2016-08-31
SCID: 54.1/wj6thkse
Discuss with AI
NMR fingerprintingbiosimilarity metricsmonoclonal antibodiesprotein formulationstructural comparability
Figures from the paper
Abstract (AI)
Biosimilar drug products must have a demonstrated similarity with respect to the reference product's molecules in order to ensure both the effectiveness of the drug and the patients' safety. In this paper the fusion framework of a highly sensitive NMR fingerprinting approach for conformational changes and mathematically-based biosimilarity metrics is introduced. The final goal is to translate the complex spectral information into biosimilarity scores, which are then used to estimate the degree of similarity between the biosimilar and the reference product. The proposed method was successfully applied to a small protein, i.e., filgrastim (neutropenia treatment), which is the first biosimilar approved in the United States, and a relatively large protein, i.e., monoclonal antibody rituximab (lymphoma treatment). This innovative approach introduces a new level of sensitivity to structural changes that are induced by, e.g., a small pH shift or other changes in the protein formulation.
Key Findings
1
Converts complex NMR spectral information into biosimilarity scores estimating similarity between biosimilar and reference molecules.
2
Introduces an integrated framework combining highly sensitive NMR fingerprinting with mathematically based biosimilarity metrics.
3
Provides enhanced sensitivity to structural changes caused by small pH shifts or other protein-formulation changes.
4
Successfully applies the method to both the small protein filgrastim and the larger monoclonal antibody rituximab.
5
Supports structural comparability assessment intended to help evaluate biosimilar effectiveness and patient safety.
Research Object
Biosimilar and reference protein drug products, including filgrastim and monoclonal antibody rituximab
Research Subject
Structural and conformational similarity between biosimilar and reference products, including sensitivity to formulation-induced changes
Publication Details
Publication Date
2016-08-31
Journal
Publisher
ISSN
Cited by
48
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest